GLP-1s Being Studied For Effect On Addiction

There was about 40% average reduction in pain for 407 people with knee osteoarthritis in a clinical trial of semaglutide, more commonly known as Ozempic. The results have surprised even experts and add to a growing list of potential benefits of GLP-1s beyond what they’ve already been approved for. Clinical trials are ongoing in areas like kidney disease, addiction, Parkinson’s, Alzheimer’s, depression and schizophrenia. Initial results seem promising so far, but a crucial question continues to be how will our health system handle the costs of these drugs?